Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%

Published 04/17/2018, 12:53 PM
© Reuters.  Eiger's lonafarnib significantly reduced HDV in patients with low viral loads in mid-stage study; shares up 2%
  • Eiger BioPharmaceuticals (EIGR +1.8%) says a sub-analysis of its Phase 2 LOWR-2 study assessing lonafarnib + ritonavir in patients with hepatitis D virus (HDV) infection demonstrated high response rates in those with low baseline viral loads. The data were presented at The International Liver Congress in Paris.
  • After 24 weeks of treatment, 100% of patients with baseline viral loads no greater than 4 log experienced reductions in viral loads to below the limit of quantitation.
  • In patients with high baseline viral levels (>4 log), 50% experienced reductions below the limit of quantitation and 88% achieved at least a 2 log (100x) decline at week 24.
  • Previously: FDA signs off on single registration trial for Eiger Bio's lonafarnib in HDV; shares up 3% premarket (March 21)
  • Now read: Taiwan Liposome Company Files Terms For U.S. IPO


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.